In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...

A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

In their landmark 1961 paper on the lac operon, Nobel laureates François Jacob and Jacques Monod speculated that RNA might control gene activity in bacteria through base-pairing interactions. But once ...

As reported by Reuters, the Patent Trial and Appeal Board found that Broad scientists had conceived the practical eukaryotic ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...

One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR gene editing is a genetic technique that removes mutated genes and replaces them with nonmutated ones. While some research indicates it may help with vision, there is no conclusive evidence.

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.